# US 2021/0276940 A1 · Prostacyclin compounds, compositions and methods of use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0276940 A1
- Document ID: US20210276940A1
- Status: Published application
- Kind: A1
- Application number: 17/186,658
- Filed: 2021-02-26
- Published: 2021-09-09
- Earliest claimed: 2013-10-25
- Assignees: Insmed Incorporated
- Applicants: Insmed Incorporated
- Inventors: Vladimir MALININ; Walter PERKINS; Franziska LEIFER; Donna KONICEK; Zhili LI; Adam PLAUNT
- Web page: https://patentgrep.com/patent/US20210276940A1

## CPC

- A61K 47/6929: {the form being a nanoparticle, e.g. an immuno-nanoparticle}
- C07C 69/734: Ethers
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/0043: {Nose}
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 9/0073: {Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy; (nasal sprays A61K9/0043; inhalation of vapours of volatile or heated drugs, e.g. essential oils or nicotine, A61K9/007; devices A61M)}
- A61K 9/0075: {for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles}
- A61K 9/0078: {for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions}
- A61K 9/10: Dispersions; Emulsions
- A61K 9/14: Particulate form, e.g. powders, {Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles (microspheres A61K9/16; microcapsules A61K9/50; nanocapsules, nanoparticles of the matrix type A61K9/51)}
- A61K 9/51: Nanocapsules; {Nanoparticles; (nanotubes A61K9/0092; polymeric micelles A61K9/1075; polymersomes A61K9/1273; pure drug nanoparticles A61K9/14; drug nanoparticles with adsorbed surface modifiers A61K9/141; conjugates, e.g. between drug and non-active nanoparticles, A61K47/50; preparations for in vivo diagnosis A61K49/00; with radioactive substances A61K51/00)}
- A61K 31/165: having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K 31/216: of acids having aromatic rings, e.g. benactizyne, clofibrate
- A61K 31/225: Polycarboxylic acids
- A61K 47/06: Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K 47/14: Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
- A61K 47/24: containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
- A61K 47/28: Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
- A61K 47/34: Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers (A61K47/10 takes precedence)
- A61K 47/543: {Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine}
- A61K 47/544: {Phospholipids}
- A61K 47/60: the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- A61K 47/6907: {the form being a microemulsion, nanoemulsion or micelle}
- A61M 15/0085: {using ultrasonics (spraying or atomising liquids using ultrasonic vibrations in general B05B17/06)}
- A61M 15/009: {using medicine packages with incorporated spraying means, e.g. aerosol cans (pocket atomiser of the injector type A61M11/08)}
- A61M 16/14: by mixing different fluids, one of them being in a liquid phase
- A61P 9/12: Antihypertensives
- A61P 11/00: Drugs for disorders of the respiratory system
- C07C 69/712: the hydroxy group of the ester being etherified with a hydroxy compound having the hydroxy group bound to a carbon atom of a six-membered aromatic ring
- C07C 69/736: the hydroxy group of the ester being etherified with a hydroxy compound having the hydroxy group bound to a carbon atom of a six-membered aromatic ring
- C07C 69/753: of polycyclic acids
- C07C 235/20: having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C 235/22: having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
- A61M 2202/064: Powder
- C07C 2601/18: with a ring being at least seven-membered
- C07C 2603/14: Benz[f]indenes; Hydrogenated benz[f]indenes
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)}
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Prostacyclin compounds and compositions comprising the same are provided herein. Specifically, prostacyclin compounds comprising treprostinil covalently linked to a linear C5-C18 alkyl, branched C5-C18 alkyl, linear C2-C18 alkenyl, branched C3-C18 alkenyl, aryl, aryl-C1-C18 alkyl or an amino acid or a peptide (e.g., dipeptide, tripeptide, tetrapeptide) are described. The linkage, in one embodiment, is via a carbamate, amide or ester bond. Prostacyclin compounds provided herein can also include at least one hydrogen atom substituted with at least one deuterium atom. Methods for treating pulmonary hypertension (e.g., pulmonary arterial hypertension) and portopulmonary hypertension are also provided.

## Claims

### Claim at position 1

-180. (canceled)

### Claim 181

A method of treating pulmonary hypertension (PH) associated with interstitial lung disease in a patient in need thereof, comprising administering to the patient via pulmonary administration, a composition comprising an effective amount of a compound of Formula (II), or a pharmaceutically acceptable salt thereof:
wherein R1 is O;
R2 is tetradecyl, pentadecyl, hexadecyl, heptadecyl, or octadecyl; and
n is an integer from 0 to 5.

### Claim 182 (depends on 181)

The method of claim 181, wherein the patient is a WHO Group III PH patient.

### Claim 183 (depends on 181)

The method of claim 181, wherein R2 is linear tetradecyl, linear pentadecyl, linear hexadecyl, linear heptadecyl or linear octadecyl.

### Claim 184 (depends on 181)

The method of claim 181, wherein n is 0 or 1.

### Claim 185 (depends on 181)

The method of claim 181, wherein n is 0.

### Claim 186 (depends on 181)

The method of claim 181, wherein n is 1.

### Claim 187 (depends on 181)

The method of claim 181, wherein R2 is hexadecyl, and n is 1.

### Claim 188 (depends on 182)

The method of claim 182, wherein R2 is linear hexadecyl, and n is 1.

### Claim 189 (depends on 183)

The method of claim 183, wherein R2 is linear hexadecyl, and n is 1.

### Claim 190 (depends on 181)

The method of claim 181, wherein the composition further comprises a PEGylated lipid.

### Claim 191 (depends on 188)

The method of claim 188, wherein the composition further comprises a PEGylated lipid.

### Claim 192 (depends on 189)

The method of claim 189, wherein the composition further comprises a PEGylated lipid.

### Claim 193 (depends on 190)

The method of claim 190, wherein the PEGylated lipid comprises PEG400, PEG500, PEG1000, PEG2000, PEG3000, PEG4000 or PEG5000.

### Claim 194 (depends on 190)

The method of claim 190, wherein the PEGylated lipid comprises PEG2000.

### Claim 195 (depends on 190)

The method of claim 190, wherein the PEGylated lipid comprises cholesterol.

### Claim 196 (depends on 190)

The method of claim 190, wherein the PEGylated lipid comprises a phospholipid.

### Claim 197 (depends on 190)

The method of claim 190, wherein the PEGylated lipid comprises distearoylphosphatidylethanolamine (DSPE), dimyristoyl phosphoethanolamine (DMPE) or distearoyl glycerol (DSG).

### Claim 198 (depends on 190)

The method of claim 190, wherein the PEGylated lipid comprises distearoylphosphatidylethanolamine (DSPE).

### Claim 199 (depends on 190)

The method of claim 190, wherein the PEGylated lipid is cholesterol-PEG2000, DSPE-PEG1000, DSPE-PEG2000, or DSG-PEG2000.

### Claim 200 (depends on 190)

The method of claim 190, wherein the PEGylated lipid is DSPE-PEG2000.

### Claim 201 (depends on 191)

The method of claim 191, wherein the PEGylated lipid is DSPE-PEG2000.

### Claim 202 (depends on 192)

The method of claim 192, wherein the PEGylated lipid is DSPE-PEG2000.

### Claim 203 (depends on 181)

The method of claim 181, wherein the pulmonary administration comprises administration via a metered dose inhaler, a dry powder inhaler, or a nebulizer.

### Claim 204 (depends on 181)

The method of claim 181, wherein the composition is administered once daily.

### Claim 205 (depends on 181)

The method of claim 181, wherein the composition is administered two or more times daily.

### Claim 206 (depends on 181)

The method of claim 181, wherein the composition is in the form of a dry powder, and the pulmonary administration comprises administration via a dry powder inhaler.

### Claim 207 (depends on 187)

The method of claim 187, wherein the composition is in the form of a dry powder, and the pulmonary administration comprises administration via a dry powder inhaler.

### Claim 208 (depends on 188)

The method of claim 188, wherein the composition is in the form of a dry powder, and the pulmonary administration comprises administration via a dry powder inhaler.

### Claim 209 (depends on 189)

The method of claim 189, wherein the composition is in the form of a dry powder, and the pulmonary administration comprises administration via a dry powder inhaler.

### Claim 210 (depends on 204)

The method of claim 204, wherein the composition is in the form of a dry powder, and the pulmonary administration comprises administration via a dry powder inhaler.

### Claim 211 (depends on 205)

The method of claim 205, wherein the composition is in the form of a dry powder, and the pulmonary administration comprises administration via a dry powder inhaler.
